M
MacroGenics Inc (MGNX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$2.17
-0.03 (-1.36%)
Market Cap: $140.60M
Last updated: Nov 17, 2026 at 11:06 AM ET
MacroGenics Inc (MGNX) Valuation Multiples
MacroGenics (MGNX) trades at 1.2x sales and 5.5x book value. Its P/S of 1.2x is below its 5-year median of 2.2x. Its forward P/E is 61.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 61.0x |
| Price to sales | 1.2x |
| Price to book | 5.5x |
| PEG | N/A |
| FCF yield | -29.9% |
Historical Medians
Against its 10-year medians, its P/S is 79.3% below 5.8x and its P/B is 96.4% above 2.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.2x | 2.2x | 5.8x |
| P/B | 5.5x | 2.4x | 2.8x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 0.9x in 2025 to 12.4x in 2021. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $1.61 | 0.9x | 1.8x |
| 2024 | $3.25 | 1.4x | 1.8x |
| 2023 | $9.62 | 10.1x | 3.9x |
| 2022 | $6.71 | 2.7x | 2.9x |
| 2021 | $16.05 | 12.4x | 4.1x |
| 2020 | $22.86 | 11.5x | 4.2x |
| 2019 | $10.88 | 8.2x | 2.3x |
| 2018 | $12.70 | 9.0x | 2.4x |
| 2017 | $19.00 | 4.4x | 2.3x |
| 2016 | $20.44 | 7.7x | 2.7x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MGNX
What is MGNX's forward P/E ratio?
MacroGenics has a forward P/E ratio of 61.0x.
Is MGNX stock overvalued?
GNG's valuation label for MGNX is Fairly valued.
What is MGNX's price to sales ratio?
MacroGenics has a price to sales ratio of 1.2x.
MGNX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts